New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

ASCENTAGE PHARMA GROUP INTERNATIONAL

Contributing Author

Recent Articles by ASCENTAGE PHARMA GROUP INTERNATIONAL

Oct-07	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025 AAPG GlobeNewswire
Aug-25	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025 AAPG GlobeNewswire
Aug-20	Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates AAPG GlobeNewswire
Aug-17	Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA AAPG GlobeNewswire
Aug-07	Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 AAPG GlobeNewswire
Aug-01	Ascentage Pharma to Participate in Evercore China Biotech Summit AAPG GlobeNewswire
Jul-23	Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025 AAPG GlobeNewswire
Jul-17	Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement AAPG GlobeNewswire
Jul-14	Ascentage Pharma Announces Pricing of Top-Up Placement AAPG GlobeNewswire
Jul-14	Ascentage Pharma Announces Proposed Top-Up Placement AAPG GlobeNewswire
Jul-10	Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL AAPG GlobeNewswire
Jul-07	Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance AAPG GlobeNewswire
Jun-15	EHA 2025 Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL AAPG GlobeNewswire
Jun-09	Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress AAPG GlobeNewswire
Jun-02	Live from ASCO 2025 Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report AAPG GlobeNewswire
Jun-02	Live from ASCO 2025 Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors AAPG GlobeNewswire
May-22	Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 AAPG GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.